Dennis E Hallahan
Overview
Explore the profile of Dennis E Hallahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
2953
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh A, Lewis C, Boas C, Diebolder P, Jethva P, Rhee A, et al.
Clin Cancer Res
. 2024 Jan;
30(7):1293-1306.
PMID: 38277241
Purpose: Tax-interacting protein 1 (TIP1) is a cancer-specific radiation-inducible cell surface antigen that plays a role in cancer progression and resistance to therapy. This study aimed to develop a novel...
2.
Singh A, Dadey D, Rau M, FitzPatrick J, Shah H, Saikia M, et al.
Biomed Pharmacother
. 2023 Aug;
166:115341.
PMID: 37625322
Non-small-cell lung cancer (NSCLC) and glioblastoma (GB) have poor prognoses. Discovery of new molecular targets is needed to improve therapy. Tax interacting protein 1 (TIP1), which plays a role in...
3.
Kapoor V, Singh A, Lewis C, Deore S, Hallahan D
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328459
Therapeutic antibodies used to treat cancer are effective in patients with advanced-stage disease. For example, antibodies that activate T-lymphocytes improve survival in many cancer subtypes. In addition, antibody-drug conjugates effectively...
4.
Perkins S, Hallahan D, Schwarz J
Int J Radiat Oncol Biol Phys
. 2021 Jun;
110(3):918-919.
PMID: 34089690
No abstract available.
5.
Lewis C, Singh A, Hsu F, Thotala D, Hallahan D, Kapoor V
Clin Cancer Res
. 2021 Jun;
27(11):3224-3233.
PMID: 34074654
Purpose: We recently discovered that anti-TIP1 antibody activates endocytosis in cancer cells, which facilitates retention of antibody and dissociation of a conjugated drug. To improve the pharmacokinetics and cancer specificity...
6.
Zhu L, Huang Y, Lam D, Gach H, Zoberi I, Hallahan D, et al.
Int J Hyperthermia
. 2021 Mar;
38(1):498-510.
PMID: 33757406
Purpose: To evaluate the targetability of late-stage cervical cancer by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-induced hyperthermia (HT) as an adjuvant to radiation therapy (RT). Methods: Seventy-nine cervical cancer patients...
7.
Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow G, et al.
Nat Commun
. 2020 Nov;
11(1):6037.
PMID: 33247158
Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major role in drug resistance in MM. Drug delivery with...
8.
Zhu L, Lam D, Pacia C, Gach H, Partanen A, Talcott M, et al.
Int J Hyperthermia
. 2020 Oct;
37(1):1159-1173.
PMID: 33003967
Purpose: To characterize temperature fields and tissue damage profiles of large-volume hyperthermia (HT) induced by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) in deep and superficial targets in a porcine model....
9.
Singh A, Kapoor V, Thotala D, Hallahan D
Oncotarget
. 2020 Jul;
11(27):2647-2659.
PMID: 32676166
Resistance to radiation therapy is a significant problem in the treatment of non-small cell lung cancer (NSCLC). There is an unmet need to discover new molecular targets for drug development...
10.
Baumann B, Hallahan D, Michalski J, Perez C, Metz J
Br J Cancer
. 2020 Jun;
123(6):869-870.
PMID: 32555364
Concurrent chemo-radiotherapy is a commonly employed curative treatment approach for locally advanced cancers but is associated with considerable morbidity. Chemo-radiotherapy using proton therapy may be able to reduce side effects...